Advertisement
Dennis Podlesak, Chairman of the Board of Regado, stated, "Dr. Mazzo'sappointment comes at an important growth phase for the Company. The data fromour ongoing Phase IIa study of the REG1 Anticoagulation System are expectedlater this year. This is the first study of the REG1 system in patientsundergoing percutaneous coronary intervention. Dr. Mazzo's senior leadershipexperience, his strong scientific background and commercial and regulatoryexpertise will be invaluable to the Company as Regado advances and expands itsclinical development programs."
Advertisement
Throughout his career in the pharmaceutical industry, Dr. Mazzo hasacquired a thorough understanding of the drug development process fromdiscovery through manufacturing, launch and commercialization. Prior tojoining Chugai, Dr. Mazzo held positions of increasing responsibility withMerck & Co., Baxter, Rhone-Poulenc Rorer, Hoechst Marion Roussel, andSchering-Plough.
Dr. Mazzo commented, "I am excited for the opportunity to lead Regadothrough its next stage of growth. My primary goals are to build upon theCompany's established success and further harness the great potential inRegado's lead programs and discovery platform. The Company is unique in itsfocus on developing aptamer therapeutics paired with agents that can directlymodulate their activity. This has the potential to provide unprecedentedcontrol to the physician and represents an evolution for patient care in thehospital setting."
Dr. Mazzo currently is Non-Executive Chairman of Psivida, Inc. and aDirector of Avanir Pharmaceuticals. He earned a Bachelor of Arts degree inthe Honors Program (Interdisciplinary Humanities) and a Bachelor of Sciencedegree in Chemistry from Villanova University. In addition, Dr. Mazzoreceived his Master of Science degree in Chemistry and his Ph.D. degree inAnalytical Chemistry from the University of Massachusetts, Amherst. He wasalso a research fellow at the Ecole Polytechnique Federale de Lausanne,Switzerland.
About Regado Biosciences
Regado Biosciences is pioneering a new therapeutic field with thediscovery and development of drug:antidote systems. These systems compriseaptamer therapeutics that can be directly controlled by a specific and matchedoligonucleotide agent. Regado's technology is designed to give physicians theability to directly control and fine tune each product's therapeutic effect.This control and flexibility allows physicians to meet the individual needs ofeach patient independent of the setting. A spin-out of the Department ofSurgery at Duke University Medical Center, Regado was created to answer thetherapeutic needs identified by its scientific founders and clinical advisors.
The Company's proprietary platform technology enables the discovery ofoligonucleotide-based drug-modulating pairs to any target protein. Regadoinitially is focusing its discovery and development efforts on acute careinjectable antithrombotics, a multi-billion dollar market in need oftherapeutics with improved safety profiles.
Current investors in Regado include Domain (Princeton, NJ), QuakerBioVentures (Philadelphia, PA), Aurora Funds (Durham, NC) and Caxton AdvantageLife Sciences Fund (New York, NY), as well as individual investors, includingRobert Kierlin.
SOURCE Regado Biosciences
